Novo Nordisk A/S

Common Name

Novo Nordisk

Country

Denmark

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

78,387

Ticker

NOVO B

Exchange

NASDAQ COPENHAGEN A/S

Website

www.novonordisk.com

Description

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, ... Show more

Financial Statements of Novo Nordisk

Below are the financial statements of Novo Nordisk, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of DKK	2024	2023
Assets	—	—
Intangible assets	111,090^a	60,406^a
Property, plant and equipment	162,488^a	90,961^a
Investments in associated companies	400^a	410^a
Deferred income tax assets	24,627^a	20,380^a
Other receivables and prepayments	4,016^a	1,430^a
Other financial assets	2,277^a	1,253^a
Total non-current assets	304,898^a	174,840^a
Inventories	40,849^a	31,811^a
Trade receivables	71,949^a	64,770^a
Tax receivables	2,853^a	2,423^a
Other receivables and prepayments	12,612^a	8,068^a
Marketable securities	10,653^a	15,838^a
Derivative financial instruments	6,326^a	2,344^a
Cash at bank	15,655^a	14,392^a
Total current assets	160,897^a	139,646^a
Total assets	465,795^a	314,486^a
Equity and liabilities	—	—
Share capital	446^a	451^a
Treasury shares	-2^a	-5^a
Retained earnings	144,448^a	104,839^a
Other reserves	-1,406^a	1,276^a
Total equity	143,486^a	106,561^a
Borrowings	89,674^a	20,528^a
Deferred income tax liabilities	5,426^a	10,162^a
Retirement benefit obligations	903^a	742^a
Other liabilities	23^a	189^a
Provisions	8,755^a	6,649^a
Total non-current liabilities	104,781^a	38,270^a
Borrowings	13,113^a	6,478^a
Trade payables	28,846^a	25,606^a
Tax payables	9,716^a	7,116^a
Other liabilities	37,993^a	28,705^a
Derivative financial instruments	7,531^a	1,272^a
Provisions	120,329^a	100,478^a
Total current liabilities	217,528^a	169,655^a
Total liabilities	322,309^a	207,925^a
Total equity and liabilities	465,795^a	314,486^a

Verified Sources Behind Novo Nordisk’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Novo Nordisk’s data sources below and access millions more through our Disclosure Search.

a. Novo Nordisk's Annual Report 2024

Trace every data point back to Novo Nordisk’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Novo Nordisk A/S

Financial Statements of Novo Nordisk

Verified Sources Behind Novo Nordisk’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

GN Store Nord A/S

Ascendis Pharma A/S

H Lundbeck A/S

Ambu A/S

Demant A/S

Coloplast A/S